Richard L Tannen1, Mark G Weiner, Dawei Xie, Kurt Barnhart. 1. Department of Medicine, University of Pennsylvaniua School of Medicine, 36th and Hamilton Walk, Philadelphia, PA 19104, USA. tannen@mail.med.upenn.edu
Abstract
BACKGROUND: In the Women's Health Initiative Randomized Controlled Trial (WHI RCT), estrogen-only treatment compared with combined estrogen-progestin treatment resulted in less coronary artery disease, no increase in breast cancer and no reduction in colorectal cancer. Since we previously reasonably replicated the combined estrogen-progestin WHI RCT using the UK General Practice Research Database (GPRD), estrogen-only treatment was investigated using a similar methodology. METHODS: This GPRD study simulated the estrogen-only WHI RCT of women who had undergone a hysterectomy except for randomization. The primary analysis examined 11 572 unexposed and 6890 Exposed women (aged 55-79) treated withconjugated equine estrogen and was compared with the combined estrogen-progestin GPRD study. RESULTS: At baseline, women with a hysterectomy exhibited more cardiovascular disease than those with an intact uterus. In the estrogen-only GPRD study, adjusted hazard ratios (HRs) were 0.50 (0.38-0.67) for myocardial infarction (MI), 1.13 (0.91-1.41) for breast cancer, and 1.18 (0.72-1.92) for colorectal cancer. Compared to the HRs in the estrogen-progestin GPRD study, the estrogen-only results are significantly lower for MI and breast cancer and higher for colon cancer, a pattern similar to the WHI RCT study comparisons. CONCLUSIONS: This study confirms that post-menopausal women in the overall population respond differently to estrogen-only treatment compared with estrogen-progestin treatment, due to different hormone regimens and/or increased cardiovascular disease in hysterectomized women.
RCT Entities:
BACKGROUND: In the Women's Health Initiative Randomized Controlled Trial (WHI RCT), estrogen-only treatment compared with combined estrogen-progestin treatment resulted in less coronary artery disease, no increase in breast cancer and no reduction in colorectal cancer. Since we previously reasonably replicated the combined estrogen-progestin WHI RCT using the UK General Practice Research Database (GPRD), estrogen-only treatment was investigated using a similar methodology. METHODS: This GPRD study simulated the estrogen-only WHI RCT of women who had undergone a hysterectomy except for randomization. The primary analysis examined 11 572 unexposed and 6890 Exposed women (aged 55-79) treated with conjugated equine estrogen and was compared with the combined estrogen-progestin GPRD study. RESULTS: At baseline, women with a hysterectomy exhibited more cardiovascular disease than those with an intact uterus. In the estrogen-only GPRD study, adjusted hazard ratios (HRs) were 0.50 (0.38-0.67) for myocardial infarction (MI), 1.13 (0.91-1.41) for breast cancer, and 1.18 (0.72-1.92) for colorectal cancer. Compared to the HRs in the estrogen-progestin GPRD study, the estrogen-only results are significantly lower for MI and breast cancer and higher for colon cancer, a pattern similar to the WHI RCT study comparisons. CONCLUSIONS: This study confirms that post-menopausal women in the overall population respond differently to estrogen-only treatment compared with estrogen-progestin treatment, due to different hormone regimens and/or increased cardiovascular disease in hysterectomized women.
Authors: Ross L Prentice; Mary Pettinger; Shirley A A Beresford; Jean Wactawski-Wende; F Allan Hubbell; Marcia L Stefanick; Rowan T Chlebowski Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-05 Impact factor: 4.254
Authors: David Limsui; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Daniel J Weisenberger; Peter W Laird; Charles F Lynch; Kristin E Anderson; Amy J French; Robert W Haile; Lisa J Harnack; John D Potter; Susan L Slager; Thomas C Smyrk; Stephen N Thibodeau; James R Cerhan; Paul J Limburg Journal: Gut Date: 2011-10-24 Impact factor: 23.059
Authors: Cheryl Ritenbaugh; Janet L Stanford; LieLing Wu; James M Shikany; Robert E Schoen; Marcia L Stefanick; Vicky Taylor; Cedric Garland; Gail Frank; Dorothy Lane; Ellen Mason; S Gene McNeeley; Joao Ascensao; Rowan T Chlebowski Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-09-30 Impact factor: 4.254
Authors: Michael S Simon; Rowan T Chlebowski; Jean Wactawski-Wende; Karen C Johnson; Andrew Muskovitz; Ikuko Kato; Alicia Young; F Allan Hubbell; Ross L Prentice Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Anna H Wu; Kimberly D Siegmund; Tiffany I Long; Wendy Cozen; Peggy Wan; Chiu-Chen Tseng; Darryl Shibata; Peter W Laird Journal: Carcinogenesis Date: 2010-01-11 Impact factor: 4.944